- Home
- MVO vs SKYE Comparison
MVO vs SKYE Comparison
Compare MVO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MVO | SKYE |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.9M | 44.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MVO | SKYE |
|---|---|---|
| Price | $1.82 | $1.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | 55.1K | ★ 497.0K |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 17.46% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $7.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.85 | $0.68 |
| 52 Week High | $13.95 | $5.75 |
Technical Indicators
Market Signals| Indicator | MVO | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 53.22 | 50.12 |
| Support Level | $1.55 | $0.95 |
| Resistance Level | $2.42 | $1.07 |
| Average True Range (ATR) | 0.32 | 0.10 |
| MACD | 0.07 | 0.02 |
| Stochastic Oscillator | 57.80 | 59.36 |
Price Performance
Historical ComparisonAbout MVO MV Oil Trust Units of Beneficial Interests
MV Oil Trust is a statutory trust. Its underlying properties consist of MV Partners, LLC's (MV Partners) net interests in all of its oil and natural gas properties, which are located in the Mid-Continent region in the States of Kansas and Colorado. These properties include producing oil and gas wells.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.